S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
Economic and National Security Threats Create Lithium Bonanza (Ad)
'The Sacrifice Zone': Myanmar bears cost of green energy
Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
Ralph Lauren Is A Retail Stock You Can Buy And Hold
Economic and National Security Threats Create Lithium Bonanza (Ad)
Closing prices for crude oil, gold and other commodities
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
Economic and National Security Threats Create Lithium Bonanza (Ad)
'The Sacrifice Zone': Myanmar bears cost of green energy
Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
Ralph Lauren Is A Retail Stock You Can Buy And Hold
Economic and National Security Threats Create Lithium Bonanza (Ad)
Closing prices for crude oil, gold and other commodities
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
Economic and National Security Threats Create Lithium Bonanza (Ad)
'The Sacrifice Zone': Myanmar bears cost of green energy
Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
Ralph Lauren Is A Retail Stock You Can Buy And Hold
Economic and National Security Threats Create Lithium Bonanza (Ad)
Closing prices for crude oil, gold and other commodities
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
Economic and National Security Threats Create Lithium Bonanza (Ad)
'The Sacrifice Zone': Myanmar bears cost of green energy
Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
Ralph Lauren Is A Retail Stock You Can Buy And Hold
Economic and National Security Threats Create Lithium Bonanza (Ad)
Closing prices for crude oil, gold and other commodities
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
NASDAQ:GBT

Global Blood Therapeutics - GBT News Headlines

$66.59
-0.01 (-0.02%)
(As of 08/9/2022 12:00 AM ET)
Add
Compare
Today's Range
$66.46
$66.66
50-Day Range
$22.30
$66.60
52-Week Range
$21.65
$73.02
Volume
7.28 million shs
Average Volume
1.73 million shs
Market Capitalization
$4.33 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$61.40
Get Global Blood Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for GBT and its competitors with MarketBeat's FREE daily newsletter.

GBT Media Mentions By Week

GBT Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

GBT
News Sentiment

0.00

0.48

Average
Medical
News Sentiment

GBT News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

GBT Articles
This Week

54

3

GBT Articles
Average Week



SourceHeadline
marketbeat.com logoSVB Leerink Lowers Global Blood Therapeutics (NASDAQ:GBT) to Market Perform
marketbeat.com - August 9 at 11:12 AM
marketbeat.com logoGlobal Blood Therapeutics (NASDAQ:GBT) Posts Quarterly Earnings Results, Misses Expectations By $0.07 EPS
marketbeat.com - August 9 at 9:17 AM
marketbeat.com logoPfizer buying spree continues with $5.4B hematology deal
marketbeat.com - August 8 at 8:41 AM
marketbeat.com logoPfizer buying spree continues with $5.4B hematology deal
marketbeat.com - August 8 at 7:51 AM
MarketBeat logoGlobal Blood Therapeutics (NASDAQ:GBT) Rating Increased to Buy at Canaccord Genuity Group
americanbankingnews.com - August 10 at 1:46 AM
benzinga.com logoGLOBAL BLOOD THERAPEUTICS, INC. ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of GBT and Encourages Investors to Contact the Firm
benzinga.com - August 9 at 11:19 PM
247wallst.com logoPfizer To Acquire Blood Disorder Drugmaker Global Blood Therapeutics For $5.4B
247wallst.com - August 9 at 1:18 PM
markets.businessinsider.com logoWhere Global Blood Therapeutics Stands With Analysts
markets.businessinsider.com - August 9 at 1:18 PM
markets.businessinsider.com logo8 Analysts Have This to Say About Global Blood Therapeutics
markets.businessinsider.com - August 9 at 1:18 PM
finance.yahoo.com logoGlobal Blood (GBT) to be Acquired by Pfizer, Misses on Earnings
finance.yahoo.com - August 9 at 1:18 PM
MarketBeat logoGlobal Blood Therapeutics (NASDAQ:GBT) Given Neutral Rating at Wedbush
americanbankingnews.com - August 9 at 8:22 AM
MarketBeat logoGlobal Blood Therapeutics (NASDAQ:GBT) Lowered to "Mkt Perform" at William Blair
americanbankingnews.com - August 9 at 6:14 AM
apnews.com logoSHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Global Blood Therapeutics, Inc. (Nasdaq – GBT)
apnews.com - August 9 at 3:17 AM
msn.com logoPfizer agrees to $5.4B deal for Global Blood Therapeutics
msn.com - August 8 at 5:05 PM
nasdaq.com logoPfizer To Buy Global Blood Therapeutics In $5.4 Bln All-cash Deal
nasdaq.com - August 8 at 5:05 PM
msn.com logoGlobal Blood Therapeutics Shares Tick Higher After Pfizer Buy Agreed
msn.com - August 8 at 5:05 PM
reuters.com logoFlush with cash, Pfizer buys Global Blood Therapeutics in $5.4 bln deal
reuters.com - August 8 at 5:05 PM
barrons.com logoPfizer Buys Global Blood Therapeutics. How the Deal Could Solve Pipeline Worries.
barrons.com - August 8 at 5:05 PM
finance.yahoo.com logoPfizer Agrees to $5.4 Billion Deal for Global Blood Therapeutics
finance.yahoo.com - August 8 at 5:05 PM
finance.yahoo.com logoWhy Global Blood Therapeutics Stock Was Trouncing the Market Today
finance.yahoo.com - August 8 at 5:05 PM
finance.yahoo.com logoWhy Pfizer's $5.4 Billion GBT Takeover Is 'Mutually Beneficial'
finance.yahoo.com - August 8 at 5:05 PM
MarketBeat logoGlobal Blood Therapeutics (NASDAQ:GBT) Sees Large Volume Increase
americanbankingnews.com - August 7 at 3:56 AM
nasdaq.com logoBiotech ETFs Rally as Global Blood Therapeutics Surges on Potential Pfizer Deal
nasdaq.com - August 6 at 9:41 PM
MarketBeat logoGlobal Blood Therapeutics (NASDAQ:GBT) Sets New 52-Week High at $48.00
americanbankingnews.com - August 6 at 5:32 AM
reuters.com logoPfizer in advanced talks to buy Global Blood Therapeutics for $5 bln - WSJ
reuters.com - August 5 at 3:45 PM
investing.com logoPfizer in Global Blood Therapeutics Takeover Talks
investing.com - August 5 at 3:45 PM
finance.yahoo.com logoPfizer, Global Blood Therapeutics In Advanced Talks For $5B Buyout Deal: Report
finance.yahoo.com - August 5 at 3:45 PM
ft.com logoPfizer in talks to buy Global Blood Therapeutics for roughly $5bn
ft.com - August 5 at 3:45 PM
finance.yahoo.com logoPfizer in Advanced Talks to Buy Global Blood Therapeutics for About $5 Billion
finance.yahoo.com - August 5 at 3:45 PM
finance.yahoo.com logoWSJ: Pfizer considering buying Global Blood Therapeutics for roughly $5 billion
finance.yahoo.com - August 5 at 3:45 PM
finance.yahoo.com logoPfizer in Talks to Buy Global Blood Therapeutics for $5 Billion, Report Says
finance.yahoo.com - August 5 at 3:45 PM
finance.yahoo.com logoPfizer in Talks to Buy Sickle-Cell Drugmaker for $5 Billion, WSJ Reports
finance.yahoo.com - August 5 at 3:45 PM
finance.yahoo.com logoWhy Global Blood Therapeutics Stock Is Vaulting Higher Today
finance.yahoo.com - August 5 at 3:45 PM
finance.yahoo.com logoPfizer Is Reportedly In 'Advanced Talks' To Buy Global Blood Therapeutics For $5 Billion
finance.yahoo.com - August 5 at 3:45 PM
finance.yahoo.com logoStrength Seen in Global Blood (GBT): Can Its 41.4% Jump Turn into More Strength?
finance.yahoo.com - August 5 at 10:44 AM
MarketBeat logoTraders Buy Large Volume of Global Blood Therapeutics Call Options (NASDAQ:GBT)
americanbankingnews.com - August 5 at 1:42 AM
theglobeandmail.com logoWhy Global Blood Therapeutics Stock Is Soaring Today
theglobeandmail.com - August 4 at 7:42 PM
investing.com logoPharmaceutical Giants Eye Global Blood Therapeutics Takeover - Bloomberg
investing.com - August 4 at 2:42 PM
finance.yahoo.com logoStock Market Lower As Crude Oil Prices Fall Below $90
finance.yahoo.com - August 4 at 2:42 PM
finance.yahoo.com logoGlobal Blood Therapeutics shares jump 34% after Bloomberg report about 'takeover interest'
finance.yahoo.com - August 4 at 9:39 AM
benzinga.com logo4GBT : Why Global Blood Therapeutics Stock Is Surging After Hours
benzinga.com - August 3 at 6:35 PM
MarketBeat logoQ3 2022 EPS Estimates for Global Blood Therapeutics, Inc. (NASDAQ:GBT) Decreased by Analyst
americanbankingnews.com - July 31 at 2:04 AM
finance.yahoo.com logoGBT to Announce Second Quarter 2022 Financial Results on Monday, August 8, 2022
finance.yahoo.com - July 29 at 8:46 AM
finance.yahoo.com logoAnalysts Estimate Regeneron (REGN) to Report a Decline in Earnings: What to Look Out for
finance.yahoo.com - July 27 at 2:39 PM
finance.yahoo.com logoEarnings Preview: Global Blood Therapeutics (GBT) Q2 Earnings Expected to Decline
finance.yahoo.com - July 26 at 1:11 PM
finance.yahoo.com logoMHRA Grants Marketing Authorization for GBT’s Oxbryta® (voxelotor) for Use in Great Britain for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Age 12 Years and Older
finance.yahoo.com - July 26 at 8:11 AM
morningstar.com logoGlobal Blood Therapeutics Inc - Stock Quote GBT
morningstar.com - July 19 at 6:16 PM
finance.yahoo.com logoGBT Initiates Expanded Access Program for Voxelotor in Patients With Sickle Cell Disease in Brazil
finance.yahoo.com - July 14 at 11:03 AM
finance.yahoo.com logoThe GBT Foundation Awards $250,000 in ACE Grants to Support Sickle Cell Disease Community-Based Organizations
finance.yahoo.com - July 13 at 9:09 AM
finance.yahoo.com logoGlobal Blood Therapeutic Stock Sees Relative Strength Rating Rise To 91
finance.yahoo.com - July 5 at 8:41 PM
finance.yahoo.com logoGlobal Blood (GBT) Initiates Phase II Study on SCD Candidate
finance.yahoo.com - June 30 at 4:31 PM
finance.yahoo.com logoWhy Global Blood Therapeutics Trended Upward Today
finance.yahoo.com - June 29 at 8:29 PM
seekingalpha.com logoGBT begins phase 2/3 clinical trial of GBT601 to treat sickle cell disease
seekingalpha.com - June 29 at 10:27 AM
finance.yahoo.com logoGBT Initiates Phase 2/3 Clinical Trial of GBT601 in Patients with Sickle Cell Disease
finance.yahoo.com - June 29 at 10:27 AM
Get Global Blood Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for GBT and its competitors with MarketBeat's FREE daily newsletter.

This page (NASDAQ:GBT) was last updated on 8/10/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.